Sexcord/ stromal ovarian tumors laboratory findings: Difference between revisions
Jump to navigation
Jump to search
| (15 intermediate revisions by the same user not shown) | |||
| Line 2: | Line 2: | ||
{{Sexcord/ stromal ovarian tumors}} | {{Sexcord/ stromal ovarian tumors}} | ||
{{CMG}}; {{AE}} | {{CMG}}; {{AE}} ;{{M.N}} | ||
==Overview== | ==Overview== | ||
[[Laboratory]] findings consistent with the [[diagnosis]] of sexcord/ stromal ovarian tumors include identifying the presence or absence of [[tumor markers]] like AMH: [[anti-Müllerian hormone]]; [[AFP]]: [[alpha-fetoprotein]]; E2: [[estradiol]]; [[hCG]]: [[human chorionic gonadotropin]]; [[LDH]]: [[lactate dehydrogenase]]; testost: [[testosterone]]; andro: [[androstenedione]]; [[Dehydroepiandrosterone|DHEA]]: dehydroepiandrostenedione; | |||
Laboratory findings consistent with the diagnosis of [ | |||
[ | |||
==Laboratory Findings== | ==Laboratory Findings== | ||
Laboratory findings consistent with the diagnosis of sexcord-stromal ovarian tumors include | *[[Laboratory]] findings consistent with the [[diagnosis]] of sexcord-stromal ovarian tumors include identifying the [[tumor markers]]<ref name="pmid8633676">{{cite journal |vauthors=Rey RA, Lhommé C, Marcillac I, Lahlou N, Duvillard P, Josso N, Bidart JM |title=Antimüllerian hormone as a serum marker of granulosa cell tumorsof the ovary: comparative study with serum alpha-inhibin and estradiol |journal=Am. J. Obstet. Gynecol. |volume=174 |issue=3 |pages=958–65 |date=March 1996 |pmid=8633676 |doi= |url=}}</ref><ref name="pmid10435065">{{cite journal |vauthors=Robertson DM, Cahir N, Burger HG, Mamers P, Groome N |title=Inhibin forms in serum from postmenopausal women with ovarian cancers |journal=Clin. Endocrinol. (Oxf) |volume=50 |issue=3 |pages=381–6 |date=March 1999 |pmid=10435065 |doi= |url=}}</ref><ref name="pmid12044923">{{cite journal |vauthors=Robertson DM, Stephenson T, Pruysers E, Burger HG, McCloud P, Tsigos A, Groome N, Mamers P, McNeilage J, Jobling T, Healy D |title=Inhibins/activins as diagnostic markers for ovarian cancer |journal=Mol. Cell. Endocrinol. |volume=191 |issue=1 |pages=97–103 |date=May 2002 |pmid=12044923 |doi= |url=}}</ref><ref name="pmid18642569">{{cite journal |vauthors=Markova D, Milchev N, Batashki I, Uchikov A |title=[Role of total inhibin in diagnosis and monitoring of ovarian cancer in postmenopausal women] |language=Bulgarian |journal=Akush Ginekol (Sofiia) |volume=47 |issue=1 |pages=16–9 |date=2008 |pmid=18642569 |doi= |url=}}</ref><ref name="pmid11836327">{{cite journal |vauthors=Robertson DM, Stephenson T, Pruysers E, McCloud P, Tsigos A, Groome N, Mamers P, Burger HG |title=Characterization of inhibin forms and their measurement by an inhibin alpha-subunit ELISA in serum from postmenopausal women with ovarian cancer |journal=J. Clin. Endocrinol. Metab. |volume=87 |issue=2 |pages=816–24 |date=February 2002 |pmid=11836327 |doi=10.1210/jcem.87.2.8198 |url=}}</ref><ref name="pmid15566459">{{cite journal |vauthors=Kurihara S, Hirakawa T, Amada S, Ariyoshi K, Nakano H |title=Inhibin-producing ovarian granulosa cell tumor as a cause of secondary amenorrhea: case report and review of the literature |journal=J. Obstet. Gynaecol. Res. |volume=30 |issue=6 |pages=439–43 |date=December 2004 |pmid=15566459 |doi=10.1111/j.1447-0756.2004.00231.x |url=}}</ref><ref name="pmid28438188">{{cite journal |vauthors=Ran S, Yu Q, Deng S, Xu L |title=Luteinizing hormone elevation in ovarian granulosa cell tumor: a case report and review of the literature |journal=J Ovarian Res |volume=10 |issue=1 |pages=30 |date=April 2017 |pmid=28438188 |pmc=5404692 |doi=10.1186/s13048-017-0327-2 |url=}}</ref><ref name="pmid28637499">{{cite journal |vauthors=Bufa A, Farkas N, Preisz Z, Poór V, Páger C, Szukits S, Farkas B, Gőcze PM |title=Diagnostic relevance of urinary steroid profiles on ovarian granulosa cell tumors: two case reports |journal=J Med Case Rep |volume=11 |issue=1 |pages=166 |date=June 2017 |pmid=28637499 |pmc=5480180 |doi=10.1186/s13256-017-1324-1 |url=}}</ref> | ||
*The following are the [[tumor markers]] found in sexcord/stromal ovarian tumors | |||
{| class="wikitable" | {| class="wikitable" | ||
| Line 31: | Line 17: | ||
| align="center" style="background: #4479BA;" | {{fontcolor|#FFF|'''Sex cord-stromal tumors'''}} | | align="center" style="background: #4479BA;" | {{fontcolor|#FFF|'''Sex cord-stromal tumors'''}} | ||
| align="center" style="background: #4479BA;" | {{fontcolor|#FFF|'''AFP'''}} | | align="center" style="background: #4479BA;" | {{fontcolor|#FFF|'''AFP'''}} | ||
| align="center" style="background: #4479BA;" | {{fontcolor|#FFF|'''hCG'''}} | |||
| align="center" style="background: #4479BA;" | {{fontcolor|#FFF|'''LDH'''}} | | align="center" style="background: #4479BA;" | {{fontcolor|#FFF|'''LDH'''}} | ||
| align="center" style="background: #4479BA;" | {{fontcolor|#FFF|'''E2'''}} | | align="center" style="background: #4479BA;" | {{fontcolor|#FFF|'''E2'''}} | ||
| Line 38: | Line 24: | ||
| align="center" style="background: #4479BA;" | {{fontcolor|#FFF|'''Androstenedione'''}} | | align="center" style="background: #4479BA;" | {{fontcolor|#FFF|'''Androstenedione'''}} | ||
| align="center" style="background: #4479BA;" | {{fontcolor|#FFF|'''DHEA'''}} | | align="center" style="background: #4479BA;" | {{fontcolor|#FFF|'''DHEA'''}} | ||
| align="center" style="background: #4479BA;" | {{fontcolor|#FFF|'''AMH'''}} | | align="center" style="background: #4479BA;" | {{fontcolor|#FFF|'''AMH'''}} | ||
|- | |- | ||
|Thecoma-fibroma | |[[Thecoma]]-[[fibroma]] | ||
| | | - | ||
| | |<nowiki>-</nowiki> | ||
| | |<nowiki>-</nowiki> | ||
| | |<nowiki>-</nowiki> | ||
| | |<nowiki>-</nowiki> | ||
| | |<nowiki>-</nowiki> | ||
| | |<nowiki>-</nowiki> | ||
| | |<nowiki>-</nowiki> | ||
| | |<nowiki>-</nowiki> | ||
|- | |- | ||
|Granulosa cell tumors | |[[Granulosa cell tumors]] | ||
| | |<nowiki>-</nowiki> | ||
| | |<nowiki>-</nowiki> | ||
| | |<nowiki>-</nowiki> | ||
| | |<nowiki>+/-</nowiki> | ||
| | |||
| | |<nowiki>+</nowiki> | ||
| | |<nowiki>+/-</nowiki> | ||
| | |<nowiki>-</nowiki> | ||
| | |<nowiki>-</nowiki> | ||
|<nowiki>+</nowiki> | |||
|- | |- | ||
|Sertoli-Leydig tumors | |[[Sertoli-Leydig cell tumour|Sertoli-Leydig tumors]] | ||
| | |<nowiki>+/-</nowiki> | ||
| | |<nowiki>-</nowiki> | ||
| | |<nowiki>-</nowiki> | ||
| | |<nowiki>+/-</nowiki> | ||
| | |<nowiki>+/-</nowiki> | ||
| | |<nowiki>+/-</nowiki> | ||
| | |<nowiki>+/-</nowiki> | ||
| | |<nowiki>+/-</nowiki> | ||
| | |<nowiki>-</nowiki> | ||
|} | |} | ||
AMH: anti-Müllerian hormone; AFP: alpha-fetoprotein; E2: estradiol; hCG: human chorionic gonadotropin; LDH: lactate dehydrogenase; testost: testosterone; andro: androstenedione; DHEA: dehydroepiandrostenedione; . | AMH: [[anti-Müllerian hormone]]; [[AFP]]: [[alpha-fetoprotein]]; E2: [[estradiol]]; [[hCG]]: [[human chorionic gonadotropin]]; [[LDH]]: [[lactate dehydrogenase]]; testost: [[testosterone]]; andro: [[androstenedione]]; [[DHEA]]: dehydroepiandrostenedione; . | ||
==References== | ==References== | ||
| Line 90: | Line 67: | ||
{{WH}} | {{WH}} | ||
{{WS}} | {{WS}} | ||
[[Category: | [[Category:Disease]] | ||
[[Category:Types of cancer]] | |||
[[Category:Gynecology]] | |||
[[Category:Up-To-Date]] | |||
[[Category:Oncology]] | |||
[[Category:Medicine]] | |||
[[Category:Gynecology]] | |||
[[Category:Surgery]] | |||
Latest revision as of 19:36, 6 May 2019
|
Sexcord/ stromal ovarian tumors Microchapters |
|
Differentiating Sexcord/ Stromal Ovarian Tumors from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Sexcord/ stromal ovarian tumors laboratory findings On the Web |
|
American Roentgen Ray Society Images of Sexcord/ stromal ovarian tumors laboratory findings |
|
Sexcord/ stromal ovarian tumors laboratory findings in the news |
|
Blogs on Sexcord/ stromal ovarian tumors laboratory findings |
|
Risk calculators and risk factors for Sexcord/ stromal ovarian tumors laboratory findings |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: ; Maneesha Nandimandalam, M.B.B.S.[2]
Overview
Laboratory findings consistent with the diagnosis of sexcord/ stromal ovarian tumors include identifying the presence or absence of tumor markers like AMH: anti-Müllerian hormone; AFP: alpha-fetoprotein; E2: estradiol; hCG: human chorionic gonadotropin; LDH: lactate dehydrogenase; testost: testosterone; andro: androstenedione; DHEA: dehydroepiandrostenedione;
Laboratory Findings
- Laboratory findings consistent with the diagnosis of sexcord-stromal ovarian tumors include identifying the tumor markers[1][2][3][4][5][6][7][8]
- The following are the tumor markers found in sexcord/stromal ovarian tumors
| Sex cord-stromal tumors | AFP | hCG | LDH | E2 | Inhibin | Testosterone | Androstenedione | DHEA | AMH |
| Thecoma-fibroma | - | - | - | - | - | - | - | - | - |
| Granulosa cell tumors | - | - | - | +/- | + | +/- | - | - | + |
| Sertoli-Leydig tumors | +/- | - | - | +/- | +/- | +/- | +/- | +/- | - |
AMH: anti-Müllerian hormone; AFP: alpha-fetoprotein; E2: estradiol; hCG: human chorionic gonadotropin; LDH: lactate dehydrogenase; testost: testosterone; andro: androstenedione; DHEA: dehydroepiandrostenedione; .
References
- ↑ Rey RA, Lhommé C, Marcillac I, Lahlou N, Duvillard P, Josso N, Bidart JM (March 1996). "Antimüllerian hormone as a serum marker of granulosa cell tumorsof the ovary: comparative study with serum alpha-inhibin and estradiol". Am. J. Obstet. Gynecol. 174 (3): 958–65. PMID 8633676.
- ↑ Robertson DM, Cahir N, Burger HG, Mamers P, Groome N (March 1999). "Inhibin forms in serum from postmenopausal women with ovarian cancers". Clin. Endocrinol. (Oxf). 50 (3): 381–6. PMID 10435065.
- ↑ Robertson DM, Stephenson T, Pruysers E, Burger HG, McCloud P, Tsigos A, Groome N, Mamers P, McNeilage J, Jobling T, Healy D (May 2002). "Inhibins/activins as diagnostic markers for ovarian cancer". Mol. Cell. Endocrinol. 191 (1): 97–103. PMID 12044923.
- ↑ Markova D, Milchev N, Batashki I, Uchikov A (2008). "[Role of total inhibin in diagnosis and monitoring of ovarian cancer in postmenopausal women]". Akush Ginekol (Sofiia) (in Bulgarian). 47 (1): 16–9. PMID 18642569.
- ↑ Robertson DM, Stephenson T, Pruysers E, McCloud P, Tsigos A, Groome N, Mamers P, Burger HG (February 2002). "Characterization of inhibin forms and their measurement by an inhibin alpha-subunit ELISA in serum from postmenopausal women with ovarian cancer". J. Clin. Endocrinol. Metab. 87 (2): 816–24. doi:10.1210/jcem.87.2.8198. PMID 11836327.
- ↑ Kurihara S, Hirakawa T, Amada S, Ariyoshi K, Nakano H (December 2004). "Inhibin-producing ovarian granulosa cell tumor as a cause of secondary amenorrhea: case report and review of the literature". J. Obstet. Gynaecol. Res. 30 (6): 439–43. doi:10.1111/j.1447-0756.2004.00231.x. PMID 15566459.
- ↑ Ran S, Yu Q, Deng S, Xu L (April 2017). "Luteinizing hormone elevation in ovarian granulosa cell tumor: a case report and review of the literature". J Ovarian Res. 10 (1): 30. doi:10.1186/s13048-017-0327-2. PMC 5404692. PMID 28438188.
- ↑ Bufa A, Farkas N, Preisz Z, Poór V, Páger C, Szukits S, Farkas B, Gőcze PM (June 2017). "Diagnostic relevance of urinary steroid profiles on ovarian granulosa cell tumors: two case reports". J Med Case Rep. 11 (1): 166. doi:10.1186/s13256-017-1324-1. PMC 5480180. PMID 28637499.